Aura Biosciences, Inc.

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing bel-sar, its lead product candidate, for cancers and other serious diseases where targeted treatment could offer a differentiated approach. The company has not yet commercialized any product and currently has no product revenue, so its business is centered on research, clinical development, regulatory execution, and building the capabilities needed for future launch. Aura’s operating model is highly dependent on the success of bel-sar, external financing, and potential collaboration or commercialization partnerships. Its long-term value proposition depends on obtaining regulatory approval and proving that bel-sar can address a meaningful patient population with acceptable safety, access, and reimbursement.

8.15

8.15

— Aura Biosciences, Inc.
%
Lead product candidate: bel-sar90% Clinical-stage therapeutic candidate being developed as the company's primary asset and future revenue driver.
Research and discovery pipeline10% Early-stage discovery work and any future product candidates the company may acquire or develop.

Aura does not currently sell a commercial product, so its near-term 'customers' are primarily investigators, clinical...

  • Clinical investigators and research institutionsprimary

    They support preclinical and clinical development of bel-sar by enrolling patients, generating data, and helping validate the program.

  • Specialty physicians and treatment centersprimary

    If approved, these providers would prescribe or administer bel-sar to patients with the relevant oncology indications.

  • Third-party payors and government reimbursement systemsprimary

    They determine coverage and reimbursement, which will be critical to patient access and commercial adoption.

  • Commercial partnerssecondary

    Potential collaborators may handle sales, marketing, and distribution if Aura does not commercialize alone.

Aura is headquartered in the United States and its current operating footprint is centered on U.S...

  • •Headquartered in the United States
  • •Current operations are primarily U.S.-based R&D and corporate functions
  • •Future commercialization may require U.S. and EU sales capabilities
  • •Potential global expansion depends on regulatory approvals and partners
  • •International IP enforcement may be more costly and less protective

Aura’s strategy is to advance bel-sar through clinical development, secure regulatory approval, and preserve the...

01
Advance bel-sar through clinical developmentshort-term

Bel-sar is the company's only product candidate and the main source of future value.

02
Secure additional financingshort-term

The company has no product revenue and will need substantial capital to fund operations until commercialization, if ever.

03
Build commercialization readinessmedium-term

If approved, Aura must decide whether to build an internal commercial organization or partner for launch.

04
Protect intellectual propertymedium-term

Patent protection and exclusivity are essential to preserving the commercial opportunity for bel-sar.

Aura faces the classic risks of a clinical-stage biotech company: it has no product revenue, ongoing losses, and a...

critical

Dependence on bel-sar as the only product candidate

If bel-sar fails clinically, is not approved, or does not achieve adoption, the company has no diversified revenue base to offset the setback.

Scope
Entire business model
Materiality
high
high

Need for additional capital

The company has no revenue and expects to fund operations through external financing, which may not be available on favorable terms.

Scope
Liquidity and development funding
Materiality
high
high

Regulatory and clinical development failure

Bel-sar must complete trials and obtain marketing approval before any product revenue can be generated.

Scope
Clinical and regulatory pathway
Materiality
high
high

Commercialization execution risk

Aura has no sales, marketing, or distribution organization and may depend on partners whose efforts could be ineffective.

Scope
Launch and market access
Materiality
high
medium

Intellectual property disputes

Patent filing, prosecution, and defense are costly, and infringement claims could delay development or require damages.

Scope
Global patent portfolio
Materiality
medium
medium

Third-party manufacturing and supply interruptions

The company relies on external manufacturers for clinical and future commercial supplies, creating operational and quality risk.

Scope
Clinical supply chain
Materiality
medium
Research and development expense recognition
Affects operating loss and comparability across periods
Liquidity and going-concern style runway assessment
Important for assessing dilution and funding risk
License and collaboration obligations
Can affect future cash outflows and reported results
Stock-based compensation
Impacts operating expenses and non-cash loss measures

CERO THERAPEUTICS HOLDINGS, INC.

CERO · Biological Products, (No Diagnostic Substances)

Tyra Biosciences, Inc.

TYRA · Pharmaceutical Preparations

Zura Bio Ltd

ZURA · Biological Products, (No Diagnostic Substances)

Aprea Therapeutics, Inc.

APRE · Pharmaceutical Preparations

Vera Therapeutics, Inc.

VERA · Pharmaceutical Preparations

BriaCell Therapeutics Corp.

BCTX · Pharmaceutical Preparations

: 11/08/2026